Growth finance for enterprise revenue teams for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install growth finance has to reflect that reality from day one.

Enterprise growth finance is not a bigger version of the startup playbook. It is running growth as a portfolio with a return-on-invested-capital lens, run under governance, procurement, and regional constraints most founders never encounter.

The value of growth finance at enterprise scale is compounded by distribution: burn discipline is what buys the next 18 months, and applied across dozens of teams the delta becomes a full quarter of pipeline.

The right shape at enterprise is a hub-and-spoke: a central team owns the model, the metric, and the tooling; regional teams own execution against local ICP nuance. Fully centralised deployments miss context; fully federated deployments diverge inside a quarter.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Growth finance is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Instrument CAC payback and gross margin as a shared metric across BUs before you argue about incentives. Anything less turns the operating review into a data debate instead of a revenue conversation.

The enterprise-specific failure mode is optimising for growth rate at any cost, magnified by the fact that governance rewards process compliance over outcome. Design controls that catch the trap without slowing the model.

Rollout takes two quarters, not two months. Pilot with one BU that already has strong ops. Publish a scorecard. Then expand — never in parallel across five regions at once.

Enterprise growth finance done right is the difference between a decade of predictable growth and a decade of restructures. Done wrong, it becomes another initiative buried under next year's slide.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing growth finance properly rather than half-heartedly across three vendors.